Recent Updates
Recently added Catalysts

Systane

Phase 2

Dry Eye | Small molecule | Ophthalmology |Abbott Laboratories|Last Updated: Feb 3, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment110
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00607776Artificial Tears Study in Mild to Moderate Dry Eye PatientsPHASE2 COMPLETED 110Jan 1, 2007Apr 1, 2007Feb 3, 2025 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Subjective ocular comfort
1 Month
Secondary Endpoints
Vision quality
1 Month
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORSystane
2EXPERIMENTALBlink tears
Interventions
NameTypeDescription
(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400DRUGDrops
SystaneDRUGDrops
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Mild to moderate dry eye * over 18 Exclusion Criteria: * No concurrent ocular disease or meds

Unlock Eligibility Criteria